{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-210739","form_type":"8-K","ticker":null,"cik":"0001821323","company_name":"Sigilon Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.446046+00:00","generated_at":"2026-06-11T15:06:26.749566+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Sigilon Therapeutics acquired by Eli Lilly for $14.92/share plus CVR; stock to be delisted","bullets":["Tender offer closed with 68.23% of shares tendered; together with parent shares, 76.61% of outstanding shares.","Each share received $14.92 cash plus one contingent value right (CVR) with potential payments up to $111.64.","All directors and executive officers resigned; replaced by Eli Lilly designees.","Nasdaq delisting requested; company intends to file Form 15 to suspend SEC reporting.","Merger completed under DGCL Section 251(h) without stockholder vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-210739","json":"https://secwatch.observer/filing/0001193125-23-210739.json","markdown":"https://secwatch.observer/filing/0001193125-23-210739.md","text":"https://secwatch.observer/filing/0001193125-23-210739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/d510415d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:06:26.749566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17b347389a","claim":"Michael C. Thompson was appointed as Treasurer at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson as President, Michael C. Thompson as Treasurer, Katie Lodato as Assistant Treasurer, Christopher Anderson as Secretary, and Jonathan Groff as Assistant Secretary, the executive officers of Purchaser immediately prior to the Effective Time, became the executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Treasurer"}],"fact_type":"executive_change"},{"claim_id":"1c706e26b1","claim":"Katie Lodato was appointed as Assistant Treasurer at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson as President, Michael C. Thompson as Treasurer, Katie Lodato as Assistant Treasurer, Christopher Anderson as Secretary, and Jonathan Groff as Assistant Secretary, the executive officers of Purchaser immediately prior to the Effective Time, became the executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Assistant Treasurer"}],"fact_type":"executive_change"},{"claim_id":"2b094c5167","claim":"Philip L. Johnson was appointed as President at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson as President, Michael C. Thompson as Treasurer, Katie Lodato as Assistant Treasurer, Christopher Anderson as Secretary, and Jonathan Groff as Assistant Secretary, the executive officers of Purchaser immediately prior to the Effective Time, became the executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"6def3e84ef","claim":"Michael C. Thompson was appointed as Director at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson, Gordon J. Brooks, Michael C. Thompson, the directors of Purchaser immediately prior to the Effective Time, became directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"785d44a9fb","claim":"John Cox resigned as director at Sigilon Therapeutics, Inc..","evidence_excerpt":"each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"85ec098f5c","claim":"Jonathan Groff was appointed as Assistant Secretary at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson as President, Michael C. Thompson as Treasurer, Katie Lodato as Assistant Treasurer, Christopher Anderson as Secretary, and Jonathan Groff as Assistant Secretary, the executive officers of Purchaser immediately prior to the Effective Time, became the executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Assistant Secretary"}],"fact_type":"executive_change"},{"claim_id":"8705697abd","claim":"Robert R. Ruffolo, Jr., Ph.D. resigned as director at Sigilon Therapeutics, Inc..","evidence_excerpt":"each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"b6d36d4ca6","claim":"Philip L. Johnson was appointed as Director at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson, Gordon J. Brooks, Michael C. Thompson, the directors of Purchaser immediately prior to the Effective Time, became directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c15ddfed25","claim":"Gordon J. Brooks was appointed as Director at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson, Gordon J. Brooks, Michael C. Thompson, the directors of Purchaser immediately prior to the Effective Time, became directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c21ab85736","claim":"Stephen N. Oesterle, M.D. resigned as director at Sigilon Therapeutics, Inc..","evidence_excerpt":"each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"c9a44c2e1a","claim":"Christopher Anderson was appointed as Secretary at Sigilon Therapeutics, Inc..","evidence_excerpt":"As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson as President, Michael C. Thompson as Treasurer, Katie Lodato as Assistant Treasurer, Christopher Anderson as Secretary, and Jonathan Groff as Assistant Secretary, the executive officers of Purchaser immediately prior to the Effective Time, became the executive officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Secretary"}],"fact_type":"executive_change"},{"claim_id":"c9ba281ba7","claim":"Kavita Patel, M.D. resigned as director at Sigilon Therapeutics, Inc..","evidence_excerpt":"each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"db81ac7486","claim":"Eric D. Shaff resigned as director at Sigilon Therapeutics, Inc..","evidence_excerpt":"each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"e470b0dd35","claim":"Rogerio Vivaldi Coelho, M.D. resigned as director at Sigilon Therapeutics, Inc..","evidence_excerpt":"each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"fb4d7210ec","claim":"Douglas G. Cole, M.D. resigned as director at Sigilon Therapeutics, Inc..","evidence_excerpt":"each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"0bb07f13e76308d6c62eabe746c857031ef171f3","claim":"Sigilon Therapeutics, Inc.: Amended and restated bylaws in their entirety.","evidence_excerpt":"and the Company’s amended and restated bylaws were amended and restated in their entirety as set forth on Annex III to the Merger Agreement (the “Amended and Restated Bylaws”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"1295388c85b2bc603b4dca772d9e1c896be2dacb","claim":"Sigilon Therapeutics, Inc.: Amended and restated certificate of incorporation in its entirety.","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, as of the Effective Time, the Company’s amended and restated certificate of incorporation was amended and restated in its entirety as set forth on Annex II to the Merger Agreement (the “Amended and Restated Certificate of Incorporation”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"46e4b970024c65856388a01bf2d988426a8fc07d","claim":"Sigilon Therapeutics, Inc. underwent a change of control involving Eli Lilly and Company for $14.92 per Share in cash plus one contingent value right per Share (closed 2023-08-11).","evidence_excerpt":"to purchase any and all of the issued and outstanding shares (the “Shares”) of common stock, par value $0.001 per Share (the “Common Stock”), of the Company in exchange for (a) $14.92 per Share, net to the stockholder in cash, without interest (the “Closing Amount”), plus one contingent value right per Share (each a “CVR”), which represents the contractual","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Eli Lilly and Company"},{"label":"Consideration","value":"$14.92 per Share in cash plus one contingent value right per Share"},{"label":"Closing","value":"2023-08-11"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}